One of our lead programs at Cypralis required a natural product fermentation process as the starting point and we turned to Hypha Discovery to help with improvements to the process.  Working closely with the Hypha scientists, under funding from an Innovate UK award, the producing strain was modified to yield over 5-fold more of our desired starting material and with a cleaner purity profile.  These modifications will enable Cypralis to transition the process to large scale to support our pre-clinical studies.  Working with the Hypha group has been a very rewarding experience and we look forward to future collaborations.”

Dr. Michael Peel, Chief Scientific Officer, Cypralis Ltd., Cambridge, UK

 

logo-scynexis

“When the need to generate, and characterize, oxidative metabolites of a complex natural product emerged, Scynexis recognized that direct synthesis may be difficult and instead turned to Hypha Discovery to explore biosynthetic  opportunities.  The Hypha team was extremely professional in their approach to the problem and rapidly identified organisms that produced the desired metabolites.  The group then went on to scale-up the biosynthesis such that full structural characterization was achieved.  Scynexis appreciates the problem solving abilities of the Hypha team and will certainly turn to their expertise for further projects when needed.”

Dr. David Angulo, Chief Medical Officer, Scynexis Inc, Jersey City, NJ, USA


“We commissioned Hypha to produce 50-200 µg of an oxidative Phenex Logometabolite where structural details were ambiguous. They provided 1mg of highly pure metabolite enabling full structure elucidation.”

Manfred Birkel, Head of DMPK, Phenex Pharmaceuticals AG, Heidelberg, Germany


incyte“We contacted Hypha Discovery to generate specific phase I and phase II metabolite standards in sufficient quantities and purity to allow structural confirmation and quantitation. Hypha exceeded expectations, providing 60mg of a phase I metabolite and over 100mg of a phase II metabolite at high purity. Hypha’s team was a pleasure to work with and communicative and responsive throughout the process. We will undoubtedly be working with Hypha Discovery in the future.”

Jason Boer, Senior Principal Investigator, Incyte Corporation, Wilmington, USA


Gilead“Upon hearing of Hypha’s expertise in microbial transformation, we were intrigued to explore whether it might be useful for exploring the incorporation of polar groups into lead molecules in ways that were independent of synthetic considerations. We piloted two compounds from two separate projects with Hypha, choosing examples that we knew to have moderate microsomal stability. We were very pleasantly surprised at the productive outcome where microbial incorporation of a hydroxyl group on a t-butyl substituent boosted the potency of a kinase inhibitor 20-fold, such that the LLE was increased by an extraordinary 2.6 units.”

Will Watkins. Senior Director, Gilead Sciences, San Francisco, USA

Sigmoid Pharma_logo

“Hypha’s biotransformation service made available materials important to support our innovative drug delivery and development programs. Their expertise and professionalism made them easy to work with and we would gladly do so again if the occasion arises.”

Dr Ivan Coulter, CEO Sigmoid Pharma, Ireland

SGAr2P

“We have used Hypha Discovery to provide samples of several pesticidal natural products by fermentation. We find them good people to work with. They provide a flexible and reliable service, meeting agreed deadlines, and so far have always provided us with the target compounds. We are pleased to recommend Hypha Discovery. Certainly we plan to continue to work with them.”

Dianne Irwin, Senior Research Chemist, Syngenta, Jealott’s Hill, UK

selcia
In the context of a customer project, Selcia requested Hypha Discovery to produce a target molecule by microbial fermentation in sufficient quantity for an exploratory chemistry programme. Not only did Hypha Discovery deliver to our full satisfaction, as an added benefit we obtained a strain with improved productivity and reproducible protocols for fermentation, extraction, and purification of the target molecule. This, in turn, resulted in a highly satisfied Selcia customer. Should the occasion arise again, I will certainly turn to Hypha Discovery first.”

Hans Fliri, Managing Director, Selcia, Essex, UK

tmo

TMO collaborated with Hypha to make use of our extensive expertise in natural products discovery and isolation.

“The Hypha Discovery team were a dream to work with. They understood the technical challenges immediately, were able to develop an effective plan to solve the issues and delivered high quality results that were able to impact directly our internal research programs.”

Dr Steven M Martin, R&D Director, TMO, Guildford, UK

biotransfer

“Hypha Discovery very efficiently purified and identified bioactive molecules from microbial extracts. The work was on behalf of major pharma and agchem companies, and Hypha Discovery certainly didn’t let us down.

Jean-Marc Seng, Managing Director, BIOtransfer, Montreuil, France

Back to Top